Cytokinetics pitches its heart drug
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.
I love the Cytokinetics story. There’s so much at stake with aficamten, not to mention all the ups and downs from previous drug-development efforts and now the speculation about a possible takeover. That’s why I invited CEO Robert Blum to sit down with me for a fireside chat at the STAT Breakthrough Summit West in San Francisco on May 16.
Blum and I are going to get into it. I promise this will be a fun and engaging conversation. You might remember that I once short-listed Blum as one of my Worst CEOs of the Year. He certainly does, as he reminded me on a prep call yesterday. I’m going to have to walk that one back, deservedly!
Get unlimited access to award-winning journalism and exclusive events.
